From lab to launch: Marketing strategies that move biotech and life science markets

Trust and credibility are no longer optional; they’re the price of entry. Attention now demands evidence, with targeting sharper than ever, and stakeholder engagement shifting to an “always-on” rhythm.

Audiences today - whether scientists, clinicians, investors, or partners - are better informed and less easily convinced. In an environment shaped by regulatory scrutiny, complex science, and repeated hype cycles, attention is no longer earned through volume. It’s earned through credibility.

No wonder then that marketing teams are responding by building continuous relationships with highly targeted stakeholders.

From volume to value: Scientific thought leadership gets serious

One of the clearest shifts? The end of the content treadmill.

“The industry is moving from publishing more to publishing better fewer assets, stronger science, clearer communication.”

Leading biotech marketing teams are abandoning "volume content" strategies in favour of a "proof plus point of view" approach. Instead of publishing more, they're publishing better; producing fewer, higher-quality assets anchored in differentiated science and communicated with clarity.

That differentiation shows up in how companies articulate mechanism of action, marker strategy, and clinical meaning, backed by a higher standard for claims substantiation and data transparency. After several hype cycles (AI, cell and gene therapy, advanced modalities), audiences have grown sceptical. Marketing must now work harder to earn belief.

ABM expands beyond sales enablement

Account-based marketing is evolving, especially across CDMOs, CROs, tools companies, tech bio platforms, and specialized service providers.

ABM programs are becoming more disciplined in how they define and prioritize target accounts, using filters like:

• Modality focus
• Development phase
• Funding stage
• Geography
• Sponsor type

Execution is also more integrated. The best 1:few and 1:1 campaigns now coordinate paid media, email, events, LinkedIn, SDR outreach, and field teams into a single orchestrated motion designed to move specific accounts through the funnel, not just hand leads to sales.

Peer channels and community-led engagement take centre stage

“Scientists don’t want to be marketed to. They want to learn from peers who’ve solved the same problems.”

Branded communities, private roundtables, and expert networks are expanding rapidly. Why? They feel more credible than broad advertising, and they match how scientists and clinicians prefer to learn, through peers, practical experience, and nuanced discussion.

This trend is reinforced by the rise of podcasts, Substack-style newsletters, and long-form explainers that meet audiences where they already spend time.

In the UK, this is especially powerful. Tighter-knit clusters like the Golden Triangle and regional innovation hubs make community and partner marketing highly effective, so relationships and networks can scale impact quickly within concentrated ecosystems.

Congress marketing goes modular and always-on

Event marketing is no longer a moment-in-time tactic. The most effective congress programs now operate as hybrid, modular, always-on strategies:

Before the event
Targeted appointment-setting and "what to watch" scientific briefings

During the event
Capture content live; short video abstracts, poster narratives, KOL soundbites

After the event
Segmented follow-up journeys tailored to stakeholder needs (investors, clinicians, partners, patient advocates)

Done well, this approach sustains attention beyond the congress floor, drives stronger response and lead generation, and keeps messaging aligned to compliance expectations.

AI is here. But governance matters more than speed

AI is actively shaping marketing workflows, but the emphasis has shifted from speed to accuracy and governance.

Teams are using AI to:

• Accelerate modular content development
• Test messaging variations
• Support localization
• Personalize sales enablement

“The cost of being fast is too high if it comes at the expense of precision.”

At the same time, organisations are putting "human-in-the-loop" review structures in place and documenting claim sources to reduce regulatory and reputational risk.

Brand building is back (and it's strategic)

Brand building is returning as a priority, particularly for clinical-stage and platform companies that need to stand out in crowded categories.

Organisations are investing more in corporate narrative and sharpening how they answer the questions that matter most to stakeholders: Why this company? Why this science? Why now? Why believe?

There's also a noticeable move toward positioning built on platform credibility - repeatability, validation, partnerships - rather than softer, more promotional language.

Importantly, the same clarity supports employer branding and recruitment marketing, which remain critical in an environment where competition for specialized talent is intense.

Reputation and differentiation: The real competitive advantage

Here's the reality: The challenge isn't just to be visible. It's to be meaningfully different and consistently credible.

The organizations winning today differentiate on substance:

• Supply chain resilience
• Trial diversity and inclusion
• Data ethics
• Responsible pricing conversations

“In biotech, transparency isn’t a nice-to-have. It’s directly tied to brand trust and continued growth”

Overall reputation and trust have become critical factors in the success of marketing campaigns and growth within the industry.

The bottom line? Transparency and brand amplification are increasingly tied to brand trust. And that trust is what drives sustained growth across the biotech and life science landscape.

What's your take? Are you seeing these trends play out for Agilent?

If you’d like to find out more about Gravity Global can help you, please get in touch and request a meeting.